The results showed that hyperoside may increase the sensitivity of cancer cells to paclitaxel by blocking pro-inflammatory and pro-survival strategies mediated by TLR4 activation mediated by TLR4, validating the beneficial combination to achieve a suitable chemosensitivity in breast cancer [93]. The gene discussed is TLR4; the disease is breast carcinoma.